A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.
Wegovy, the popular weight loss drug from Novo Nordisk , significantly reduced symptoms of a common type of heart failure in patients with obesity, according to a late-stage clinical trial released Friday.
Wegovy helped alleviate symptoms like shortness of breath, fatigue, swelling in the legs and irregular heart beat.
There were fewer serious safety events in patients who took Wegovy compared to those who took the placebo.
But more patients stopped taking Wegovy because of gastrointestinal issues, which are commonly observed with other weight loss drugs.
Persons:
Wegovy, Martin Lange, Novo, Ozempic
Organizations:
Wegovy, Novo Nordisk, Novo Nordisk's, New England, of Medicine, Nordisk
Locations:
Chicago , Illinois, Novo, U.S